ADAM17 and lung carcinoma: The same holds true for other proteins involved in IL-6 signaling like the metalloprotease ADAM17, which is not only recently identified and proposed as a target in lung cancer [142,143], but has also been implicated in HCC, where higher ADAM17 expression and the resulting activation of the receptor Notch1 correlated with poor prognosis of the patients [144].